<DOC>
	<DOCNO>NCT00411203</DOCNO>
	<brief_summary>Objective : Evidence indicate protein kinase C-PKC signal cascade may one direct target treatment mania . The aim study investigate whether PKC inhibitor-tamoxifen anti-manic property . Method : Bipolar subject manic/mixed episode randomly assign receive either tamoxifen ( 80mg/day ) identical placebo tablet 1:1 ratio three week .</brief_summary>
	<brief_title>Tamoxifen Treatment Acute Mania</brief_title>
	<detailed_description>Patients age 18-65 year , diagnose Bipolar Disorder ( BD ) , recent episode manic mixed , without psychotic feature admit inpatient unit Dokuz Eylul University , Department Psychiatry , Izmir , Turkey . Subjects recruit local community , urban area western part Turkey , surround suburb , town well country ( expert-seeking patient reach principle investigator-PI , via internet news medium ) April , 2003 June , 2006 . All diagnosis base Structured Clinical Interview DSM-IV , administer trained investigator ( AYY ) . After protocol explain patient least one first degree relative , give write informed consent participation patient trial . The study approve Turkish Ministry Health , General Directorate Drugs Pharmaceutics , Central Review Board , Local Ethical Committee Drug Investigations Dokuz Eylul University . Subject screen include medical psychiatric history , physical examination , laboratory screen include LFTs , TSH , HCG , BUN , Cr , serum toxicology . All psychotropic medication ( except benzodiazepine ) discontinue least 1 day randomization . Subjects enter study randomly assign receive PKC inhibitor , tamoxifen identical placebo tablet 1:1 ratio double-blind fashion 3 week . Computer-generated code use create randomization kit ( prepared ARGEFAR , Izmir , Turkey , contract research organization ) . The start dose tamoxifen 20 mg bid . After first treatment day , daily dose adjust upward 10 mg per day 80 mg/d divide dos . Similar tablet adjustment apply patient placebo group . Concomitant use oral lorazepam ( 2.5mg dissolve table ) allow double-blind therapy clinically indicate . In case lorazepam think ineffective symptom antipsychotic require , risperidone liquid formulation ( 2-6 mg/day ) use emergency circumstance . Those subject give risperidone assume drop time first exposure risperidone ; new subject replacement case recruit . Subjects see twice daily investigator ( AYY , SG ) call 24 hour day . Assessment tool ; Young Mania Rating Scale ( YMRS ) , Hamilton Depression Rating Scale-17 item ( HAMD-17 ) , Montgomery-Asberg Depression Rating Scale ( MADRS ) , Clinical Global Impressions-Bipolar Version Severity Illness ( CGI ) , Positive Negative Syndrome Scale ( PANSS ) side effect questionnaire administer semi-structured interview week . Vital sign weight monitor . The PI , train rating instrument blind treatment condition ( train certification Massachusetts Hospital , Bipolar Program ) , perform study assessment weekly basis use available clinical information , provide prospective daily interview investigator , staff report include security team ' observation , first degree relative report . Power calculation perform determine sample size require achieve 80 % power detect difference 0.40 response rate , assume 0.15 response rate placebo use chi-square test .05 level . Assuming 30 % drop non compliance rate , randomization kit prepare 70 subject . Following eligibility consideration drop final sample size use analysis 50 . The primary efficacy variable define reduction baseline YMRS score 3 week therapy . Positive treatment response define &gt; =50 % decrease YMRS baseline 3 week .</detailed_description>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<mesh_term>Citric Acid</mesh_term>
	<criteria>1. diagnosis BD I , recent episode , manic mixed , 2. age 1865 , 3 . Young Mania Rating Scale ( YMRS ) score &gt; 20 screen baseline , 4. provide write informed consent . 1. currently pregnant , plan become pregnant , breast feeding , 2. history coagulopathies , deep vein thrombosis , pulmonary embolus , 3. history hypersensitivity tamoxifen , 4. drug screen positive drug abuse screening , active substance abuse past 2 week substance dependence past 2 month ( except nicotine caffeine ) , 5. diagnosis schizophrenia , dementia , delirium , seizure disorder , obsessive compulsive disorder , major cardiac , hepatic renal disease unstable require medical care , 6. administration investigational drug last 30 day , 7. clinically significant suicidal homicidal ideation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Protein kinase C , tamoxifen , acute mania , clinical trial</keyword>
</DOC>